Difference between revisions of "Epirubicin (Ellence)"
Jump to navigation
Jump to search
m |
m |
||
| Line 14: | Line 14: | ||
*[[Gallbladder cancer]] | *[[Gallbladder cancer]] | ||
*[[Gastric cancer]] | *[[Gastric cancer]] | ||
| + | *[[Hepatocellular carcinoma]] | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
| + | *[[Nasopharyngeal carcinoma]] | ||
*[[Osteosarcoma]] | *[[Osteosarcoma]] | ||
*[[Small cell lung cancer]] | *[[Small cell lung cancer]] | ||
| Line 54: | Line 56: | ||
[[Category:Gallbladder cancer medications]] | [[Category:Gallbladder cancer medications]] | ||
[[Category:Gastric cancer medications]] | [[Category:Gastric cancer medications]] | ||
| + | [[Category:Hepatocellular carcinoma medications]] | ||
[[Category:Hodgkin lymphoma medications]] | [[Category:Hodgkin lymphoma medications]] | ||
| + | [[Category:Nasopharyngeal carcinoma medications]] | ||
[[Category:Osteosarcoma medications]] | [[Category:Osteosarcoma medications]] | ||
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
Revision as of 01:23, 16 May 2022
General information
Class/mechanism: Anthracycline; binds and intercalates DNA, which triggers DNA cleavage by topoisomerase II; inhibits DNA/RNA synthesis. Inhibits DNA helicase activity, preventing enzymatic separation of double-stranded DNA.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Breast cancer
- Cholangiocarcinoma
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Gallbladder cancer
- Gastric cancer
- Hepatocellular carcinoma
- Hodgkin lymphoma
- Nasopharyngeal carcinoma
- Osteosarcoma
- Small cell lung cancer
- Soft tissue sarcoma
- Testicular cancer
Diseases for which it was used
Patient drug information
- Epirubicin (Ellence) patient drug information (Chemocare)[3]
- Brief patient counseling information can be found on pages 15-16 of the Epirubicin (Ellence) package insert[1]
- Epirubicin (Ellence) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 9/15/1999: Initial approval as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
Also known as
- Generic name: 4-epi-doxorubicin, epidoxorubicin
- Brand names: Alrubicin, Anthracin, Binarin, Bioepicyna, Crisabon, E.P.R Elvetium, Ellence, Epidoxo, Epifil, Epilem, Epirubicine, Epizin, Epricin, Eracin, Famorubicin, Farmorubicin, Farmorubicina, Farmorubicine, Pharmorubicin, Riboepi, Rubifarm
References
Categories:
- Drugs
- Intravenous medications
- Vesicant
- Anthracyclines
- Topoisomerase inhibitors
- Human DNA synthesis inhibitors
- Breast cancer medications
- Cholangiocarcinoma medications
- Diffuse large B-cell lymphoma medications
- Esophageal adenocarcinoma medications
- Esophageal cancer medications
- Gallbladder cancer medications
- Gastric cancer medications
- Hepatocellular carcinoma medications
- Hodgkin lymphoma medications
- Nasopharyngeal carcinoma medications
- Osteosarcoma medications
- Small cell lung cancer medications
- Soft tissue sarcoma medications
- Testicular cancer medications
- Ovarian cancer medications (historic)
- Pancreatic cancer medications (historic)
- FDA approved in 1999